XGN 241220 7.50C (XGN241220C7500) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

XGN241220C7500

Watchlist

0.00
0.000.00%

15min DelayTrading Nov 19 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Seeking AlphaNov 15 15:55 ET
Exagen Inc. (NASDAQ:XGN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Simply Wall StNov 15 06:13 ET
Exagen Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Yahoo FinanceNov 15 05:50 ET
Express News | Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the Avise® Ctd Platform
ReutersNov 14 16:30 ET
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE CTD Platform
GlobeNewswireNov 14 16:30 ET
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
GlobeNewswireNov 13 16:05 ET

Comments

Jaguar8

Nov 14 15:31

NEWS

$Exagen (XGN.US)$
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Moomoo AI

Mar 22 14:11

Analysts predict Exagen's revenue growth to decelerate significantly, with an expected annual growth of 3.1% till 2024, compared to its past five-year growth rate of 7.5%. This is slower than the projected 18% annual growth of its industry peers.

The Exagen Inc. (NASDAQ:XGN) Annual Results Are Out And Analysts Have Published New Forecasts

Moomoo AI

Mar 20 05:41

The low P/S ratio and slower revenue growth have led to pessimism among shareholders about the company's future prospects. The company will need a significant change in fortune to justify a higher P/S ratio in the future.

Exagen Inc.'s (NASDAQ:XGN) 28% Dip In Price Shows Sentiment Is Matching Revenues

Dannymite

Mar 18 07:51

$Exagen (XGN.US)$ estimates beat!

Moomoo AI

Oct 24, 2023 05:47

Exagen's low P/S ratio indicates investor concerns over below-average expected revenue growth. For a higher P/S ratio or share price, conditions would need to improve. The recent drop in share price may be due to this potentially less favorable outlook.

Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge